Serotonin receptors and heart valve disease-It was meant 2B

Pharmacology and Therapeutics

Volumn 132, Issue 2, 2011, Pages 146-157

  Hutcheson, Joshua D ^a   Setola, Vincent ^b   Roth, Bryan L ^b   Merryman, W David ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT2B; Heart valve; Pergolide; Phen Fen; Serotonin; Valve interstitial cell

Indexed keywords

ANOREXIGENIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CABERGOLINE; ERGOT ALKALOID; ERGOTAMINE; FENFLURAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISURIDE; METHYLERGOMETRINE; METHYSERGIDE; NORFENFLURAMINE; PERGOLIDE; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 2B RECEPTOR;

ARTICLE; CARCINOID SYNDROME; DRUG STRUCTURE; ENTEROCHROMAFFIN CELL; HUMAN; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK FACTOR; SEROTONINERGIC SYSTEM; SURGICAL TECHNIQUE; VALVULAR HEART DISEASE;

EID: 80052311025     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2011.03.008     Document Type: Review

References (141)

1. A.I. Abbas, P.B. Hedlund, X.P. Huang, T.B. Tran, H.Y. Meltzer, and B.L. Roth Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo Psychopharmacology (Berl) 205 1 2009 119 128
2. D. Abramowski, M. Rigo, D. Duc, D. Hoyer, and M. Staufenbiel Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera Neuropharmacology 34 12 1995 1635 1645
3. Y. Agmon, B.K. Khandheria, I. Meissner, J.R. Sicks, W.M. O'Fallon, and D.O. Wiebers Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a populationbased study J Am Coll Cardiol 38 3 2001 827 834 (Pubitemid 32835760)
4. E. Aikawa, P. Whittaker, M. Farber, K. Mendelson, R.F. Padera, and M. Aikawa Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering Circulation 113 10 2006 1344 1352 (Pubitemid 43739456)
5. J.A. Allen, and B.L. Roth Strategies to discover unexpected targets for drugs active at G protein-coupled receptors Annu Rev Pharmacol Toxicol 51 2011 117 144
6. A. Antonini, and W. Poewe Fibrotic heart-valve reactions to dopamineagonist treatment in Parkinson's disease Lancet Neurol 6 9 2007 826 829 (Pubitemid 47243713)
7. B.N. Armbruster, and B.L. Roth Mining the receptorome J Biol Chem 280 7 2005 5129 5132 (Pubitemid 40279980)
8. W.S. Aronow, C. Ahn, I. Kronzon, and M.E. Goldman Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons Am J Cardiol 88 6 2001 693 695 (Pubitemid 32831111)
9. K. Balachandran, S. Konduri, P. Sucosky, H. Jo, and A.P. Yoganathan An ex vivo study of the biological properties of porcine aortic valves in response to circumferential cyclic stretch Ann Biomed Eng 34 11 2006 1655 1665 (Pubitemid 44704821)
10. K. Balachandran, P. Sucosky, H. Jo, and A.P. Yoganathan Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease Am J Physiol Heart Circ Physiol 296 3 2009 H756 764
11. K. Balachandran, P. Sucosky, H. Jo, and A.P. Yoganathan Elevated cyclic stretch induces aortic valve calcification in a bone morphogenic protein-dependent manner Am J Pathol 177 1 2010 49 57
12. S.M. Banas, S. Doly, K. Boutourlinsky, S.L. Diaz, A. Belmer, and J. Callebert Deconstructing antiobesity compound action: requirement of serotonin 5-HT2B receptors for dexfenfluramine anorectic effects Neuropsychopharmacology 36 2 2011 423 433
13. N.M. Barnes, and T. Sharp A review of central 5-HT receptors and their function Neuropharmacology 38 8 1999 1083 1152 (Pubitemid 29292403)
14. J.A. Benton, H.B. Kern, L.A. Leinwand, P.D. Mariner, and K.S. Anseth Statins block calcific nodule formation of valvular interstitial cells by inhibiting alpha-smooth muscle actin expression Arterioscler Thromb Vasc Biol 29 11 2009 1950 1957
15. M. Berger, J.A. Gray, and B.L. Roth The expanded biology of serotonin Annu Rev Med 60 2009 355 366
16. S. Bhattacharyya, A.H. Schapira, D.P. Mikhailidis, and J. Davar Drug-induced fibrotic valvular heart disease Lancet 374 9689 2009 577 585
17. K. Boutet, I. Frachon, Y. Jobic, C. Gut-Gobert, C. Leroyer, and D. Carlhant-Kowalski Fenfluramine-like cardiovascular side-effects of benfluorex Eur Respir J 33 3 2009 684 688
18. B.S. Brooke, J.P. Habashi, D.P. Judge, N. Patel, B. Loeys, and H.C. Dietz III Angiotensin II blockade and aortic-root dilation in Marfan's syndrome N Engl J Med 358 26 2008 2787 2795 (Pubitemid 351930853)
19. A.H. Chester, and P.M. Taylor Molecular and functional characteristics of heart-valve interstitial cells Philos Trans R Soc Lond B Biol Sci 362 1484 2007 1437 1443 (Pubitemid 47201768)
20. D.S. Choi, and L. Maroteaux Immunohistochemical localisation of the serotonin 5-HT2B receptor in mouse gut, cardiovascular system, and brain FEBS Lett 391 1-2 1996 45 51 (Pubitemid 26325711)
21. R.D. Cohn, C. van Erp, J.P. Habashi, A.A. Soleimani, E.C. Klein, and M.T. Lisi Angiotensin II type 1 receptor blockade attenuates TGFbeta-induced failure of muscle regeneration in multiple myopathic states Nat Med 13 2 2007 204 210
22. P.J. Conn, and E. Sanders-Bush Selective 5HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex Neuropharmacology 23 8 1984 993 996 (Pubitemid 14097227)
23. H.M. Connolly, J.L. Crary, M.D. McGoon, D.D. Hensrud, B.S. Edwards, and W.D. Edwards Valvular heart disease associated with fenfluramine-phentermine N Engl J Med 337 9 1997 581 588 (Pubitemid 27360757)
24. S.J. Cowell, D.E. Newby, R.J. Prescott, P. Bloomfield, J. Reid, and D.B. Northridge A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis N Engl J Med 352 23 2005 2389 2397 (Pubitemid 40958435)
25. S. Doly, J. Bertran-Gonzalez, J. Callebert, A. Bruneau, S.M. Banas, and A. Belmer Role of serotonin via 5-HT2B receptors in the reinforcing effects of MDMA in mice PLoS One 4 11 2009 e7952
26. S. Doly, E. Valjent, V. Setola, J. Callebert, D. Herve, and J.M. Launay Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine- induced hyperlocomotion and 5-HT release in vivo and in vitro J Neurosci 28 11 2008 2933 2940 (Pubitemid 351398883)
27. S. Droogmans, B. Cosyns, H. D'Haenen, E. Creeten, C. Weytjens, and P.R. Franken Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease Am J Cardiol 100 9 2007 1442 1445 (Pubitemid 47576024)
28. S. Droogmans, B. Cosyns, and G. Van Camp Benfluorex: the last chapter of drug-induced valvular heart disease? Eur J Echocardiogr 2010
29. S. Droogmans, B. Roosens, B. Cosyns, C. Degaillier, S. Hernot, and C. Weytjens Dose dependency and reversibility of serotonin-induced valvular heart disease in rats Cardiovasc Toxicol 9 3 2009 134 141
30. M. Druce, A. Rockall, and A.B. Grossman Fibrosis and carcinoid syndrome: from causation to future therapy Nat Rev Endocrinol 5 5 2009 276 283
31. B.L. Roth The Serotonin Receptors: From Molecular Pharmacology to Human Therapeutics 2006 Humana Press
32. C.S. Elangbam Drug-induced valvulopathy: an update Toxicol Pathol 38 6 2010 837 848
33. C.S. Elangbam, L.E. Job, L.M. Zadrozny, J.C. Barton, L.W. Yoon, and L.D. Gates 5-hydroxytryptamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats Exp Toxicol Pathol 60 4-5 2008 253 262
34. C.S. Elangbam, R.M. Lightfoot, L.W. Yoon, D.R. Creech, R.S. Geske, and C.W. Crumbley 5-Hydroxytryptamine (5HT) receptors in the heart valves of cynomolgus monkeys and Sprague-Dawley rats J Histochem Cytochem 53 5 2005 671 677 (Pubitemid 40593980)
35. C.S. Elangbam, J.G. Wehe, J.C. Barton, D.L. Krull, A. Nyska, and T. Crabbs Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in the heart valves of Sprague-Dawley rats with spontaneous mitral valvulopathy-a possible exacerbation by dl-amphetamine sulfate in Fischer 344 rats? Exp Toxicol Pathol 58 2-3 2006 89 99 (Pubitemid 44635158)
36. V. Erspamer, and B. Asero Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine Nature 169 4306 1952 800 801
37. J.M. Esteve, J.M. Launay, O. Kellermann, and L. Maroteaux Functions of serotonin in hypoxic pulmonary vascular remodeling Cell Biochem Biophys 47 1 2007 33 44
38. A. Fabre, J. Marchal-Somme, S. Marchand-Adam, C. Quesnel, R. Borie, and M. Dehoux Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice Eur Respir J 32 2 2008 426 436
39. L.W. Fitzgerald, T.C. Burn, B.S. Brown, J.P. Patterson, M.H. Corjay, and P.A. Valentine Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine Mol Pharmacol 57 1 2000 75 81 (Pubitemid 30033262)
40. J.R. Graham Cardiac and pulmonary fibrosis during methysergide therapy for headache Am J Med Sci 254 1 1967 1 12
41. J.R. Graham, H.I. Suby, P.R. LeCompte, and N.L. Sadowsky Fibrotic disorders associated with methysergide therapy for headache N Engl J Med 274 7 1966 359 368
42. J.S. Grashow, A.P. Yoganathan, and M.S. Sacks Biaixal stressstretch behavior of the mitral valve anterior leaflet at physiologic strain rates Ann Biomed Eng 34 2 2006 315 325
43. B.I. Gustafsson, O. Hauso, I. Drozdov, M. Kidd, and I.M. Modlin Carcinoid heart disease Int J Cardiol 129 3 2008 318 324
44. B.I. Gustafsson, K. Tommeras, I. Nordrum, J.P. Loennechen, A. Brunsvik, and E. Solligard Long-term serotonin administration induces heart valve disease in rats Circulation 111 12 2005 1517 1522 (Pubitemid 40470647)
45. A.C. Guyton, and J.E. Hall Textbook of Medical Physiology 1996 W.B. Saunders Company Philadelphia
46. J.P. Habashi, D.P. Judge, T.M. Holm, R.D. Cohn, B.L. Loeys, and T.K. Cooper Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome Science 312 5770 2006 117 121
47. S. Hafizi, P.M. Taylor, A.H. Chester, S.P. Allen, and M.H. Yacoub Mitogenic and secretory responses of human valve interstitial cells to vasoactive agents J Heart Valve Dis 9 3 2000 454 458 (Pubitemid 30395140)
48. O. Hauso, B.I. Gustafsson, J.P. Loennechen, A.K. Stunes, I. Nordrum, and H.L. Waldum Long-term serotonin effects in the rat are prevented by terguride Regul Pept 143 1-3 2007 39 46 (Pubitemid 47212520)
49. C. Hofmann, U. Penner, R. Dorow, H.H. Pertz, S. Jahnichen, and R. Horowski Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis Clin Neuropharmacol 29 2 2006 80 86 (Pubitemid 44357157)
50. P.H. Howe Transforming growth factor Beta A.W. Thomson, M.T. Lotze, The Cytokine Handbook 2003 Elsevier Science London 1119 1141
51. C.Y. Hsu, P.E. Persons, A.P. Spada, R.A. Bednar, A. Levitzki, and A. Zilberstein Kinetic analysis of the inhibition of the epidermal growth factor receptor tyrosine kinase by Lavendustin-A and its analogue J Biol Chem 266 31 1991 21105 21112 (Pubitemid 21908580)
52. X.P. Huang, V. Setola, P.N. Yadav, J.A. Allen, S.C. Rogan, and B.J. Hanson Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment Mol Pharmacol 76 4 2009 710 722
53. F. Jaffre, P. Bonnin, J. Callebert, H. Debbabi, V. Setola, and S. Doly Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy Circ Res 104 1 2009 113 123
54. F. Jaffre, J. Callebert, A. Sarre, N. Etienne, C.G. Nebigil, and J.M. Launay Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts Circulation 110 8 2004 969 974 (Pubitemid 39128622)
55. B. Jian, J. Xu, J. Connolly, R.C. Savani, N. Narula, and B. Liang Serotonin mechanisms in heart valve disease I: serotonin-induced upregulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells Am J Pathol 161 6 2002 2111 2121 (Pubitemid 35434857)
56. A.J. Kaumann, and F.O. Levy 5-hydroxytryptamine receptors in the human cardiovascular system Pharmacol Ther 111 3 2006 674 706 (Pubitemid 44118434)
57. O. Kellermann, S. Loric, L. Maroteaux, and J.M. Launay Sequential onset of three 5-HT receptors during the 5-hydroxytryptaminergic differentiation of the murine 1 C11 cell line Br J Pharmacol 118 5 1996 1161 1170 (Pubitemid 26235614)
58. M.A. Khan, C.A. Herzog, J.V. St Peter, G.G. Hartley, R. Madlon-Kay, and C.D. Dick The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs N Engl J Med 339 11 1998 713 718 (Pubitemid 28417353)
59. A.P. Kozikowski, S.J. Cho, N.H. Jensen, J.A. Allen, A.M. Svennebring, and B.L. Roth HTS and rational drug design to generate a class of 5-HT(2 C)-selective ligands for possible use in schizophrenia ChemMedChem 5 8 2010 1221 1225
60. W.K. Kroeze, K. Kristiansen, and B.L. Roth Molecular biology of serotonin receptors structure and function at the molecular level Curr Top Med Chem 2 6 2002 507 528
61. W.K. Kroeze, D.J. Sheffler, and B.L. Roth G-protein-coupled receptors at a glance J Cell Sci 116 Pt 24 2003 4867 4869 (Pubitemid 38016693)
62. J.D. Kursar, D.L. Nelson, D.B. Wainscott, and M. Baez Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor Mol Pharmacol 46 2 1994 227 234
63. J.M. Launay, G. Birraux, D. Bondoux, J. Callebert, D.S. Choi, and S. Loric Ras involvement in signal transduction by the serotonin 5-HT2B receptor J Biol Chem 271 6 1996 3141 3147 (Pubitemid 26055615)
64. F. Le Ven, C. Tribouilloy, G. Habib, J.P. Gueffet, S. Marechaux, and J.C. Eicher Valvular heart disease associated with benfluorex therapy: results from the French multicentre registry Eur J Echocardiogr 2010
65. B. Li, S. Zhang, H. Zhang, W. Nu, L. Cai, and L. Hertz Fluoxetinemediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation Psychopharmacology (Berl) 201 3 2008 443 458
66. Y.J. Liang, L.P. Lai, B.W. Wang, S.J. Juang, C.M. Chang, and J.G. Leu Mechanical stress enhances serotonin 2B receptor modulating brain natriuretic peptide through nuclear factor-kappaB in cardiomyocytes Cardiovasc Res 72 2 2006 303 312
67. M.D. Lindner, D.B. Hodges Jr., J.B. Hogan, A.F. Orie, J.A. Corsa, and D.M. Barten An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning J Pharmacol Exp Ther 307 2 2003 682 691 (Pubitemid 37310684)
68. D. Lloyd-Jones, R.J. Adams, T.M. Brown, M. Carnethon, S. Dai, and G. De Simone Heart disease and stroke statistics-2010 update: a report from the American Heart Association Circulation 121 7 2010 e46 e215
69. P. Manivet, S. Mouillet-Richard, J. Callebert, C.G. Nebigil, L. Maroteaux, and S. Hosoda PDZ-dependent activation of nitric-oxide synthases by the serotonin 2B receptor J Biol Chem 275 13 2000 9324 9331 (Pubitemid 30185155)
70. P. Manivet, B. Schneider, J.C. Smith, D.S. Choi, L. Maroteaux, and O. Kellermann The serotonin binding site of human and murine 5-HT2B receptors: molecular modeling and site-directed mutagenesis J Biol Chem 277 19 2002 17170 17178 (Pubitemid 34967750)
71. A.V. Maricq, A.S. Peterson, A.J. Brake, R.M. Myers, and D. Julius Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel Science 254 5030 1991 432 437 (Pubitemid 21917361)
72. J.W. Mason, M.E. Billingham, and J.P. Friedman Methysergideinduced heart disease: a case of multivalvular and myocardial fibrosis Circulation 56 5 1977 889 890 (Pubitemid 8235201)
73. H.Y. Meltzer, S. Matsubara, and J.C. Lee Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values J Pharmacol Exp Ther 251 1 1989 238 246
74. W.D. Merryman Insights into (the interstitium of) degenerative aortic valve disease J Am Coll Cardiol 51 14 2008 1415 author reply 1416 (Pubitemid 351443075)
75. W.D. Merryman, G.C. Engelmayr Jr., J. Liao, and M.S. Sacks Defining biomechanical endpoints for tissue engineered heart valve leaflets from native leaflet properties Prog Pediat Cardiol 21 2 2006 153 160
76. W.D. Merryman, H.Y. Huang, F.J. Schoen, and M.S. Sacks The effects of cellular contraction on aortic valve leaflet flexural stiffness J Biomech 39 1 2006 88 96 (Pubitemid 41585012)
77. W.D. Merryman, I. Youn, H.D. Lukoff, P.M. Krueger, F. Guilak, and R.A. Hopkins Correlation between heart valve interstitial cell stiffness and transvalvular pressure: implications for collagen biosynthesis Am J Physiol Heart Circ Physiol 290 1 2006 H224 231
78. W.D. Merryman, J. Liao, A. Parekh, J.E. Candiello, H. Lin, and M.S. Sacks Differences in tissue-remodeling potential of aortic and pulmonary heart valve interstitial cells Tissue Eng 13 9 2007 2281 2289 (Pubitemid 47404443)
79. W.D. Merryman, H.D. Lukoff, R.A. Long, G.C. Engelmayr Jr., R.A. Hopkins, and M.S. Sacks Synergistic effects of cyclic tension and transforming growth factor-beta1 on the aortic valve myofibroblast Cardiovasc Pathol 16 5 2007 268 276 (Pubitemid 47375116)
80. R. Mishra, L. Zhu, R.L. Eckert, and M.S. Simonson TGF-betaregulated collagen type I accumulation: role of Src-based signals Am J Physiol Cell Physiol 292 4 2007 C1361 1369
81. E.R. Mohler, M.J. Sheridan, R. Nichols, W.P. Harvey, and B.F. Waller Development and progression of aortic valve stenosis: atherosclerosis risk factors-a causal relationship? A clinical morphologic study Clin Cardiol 14 12 1991 995 999
82. L. Monassier, M.A. Laplante, F. Jaffre, P. Bousquet, L. Maroteaux, and J. de Champlain Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice Hypertension 52 2 2008 301 307
83. C.G. Nebigil, D.S. Choi, A. Dierich, P. Hickel, M. Le Meur, and N. Messaddeq Serotonin 2B receptor is required for heart development Proc Natl Acad Sci U S A 97 17 2000 9508 9513 (Pubitemid 30650806)
84. C.G. Nebigil, J.M. Launay, P. Hickel, C. Tournois, and L. Maroteaux 5-hydroxytryptamine 2B receptor regulates cell-cycle progression: crosstalk with tyrosine kinase pathways Proc Natl Acad Sci U S A 97 6 2000 2591 2596 (Pubitemid 30159215)
85. C.G. Nebigil, P. Hickel, N. Messaddeq, J.L. Vonesch, M.P. Douchet, and L. Monassier Ablation of serotonin 5-HT(2B) receptors in mice leads to abnormal cardiac structure and function Circulation 103 24 2001 2973 2979 (Pubitemid 32578137)
86. C.G. Nebigil, F. Jaffre, N. Messaddeq, P. Hickel, L. Monassier, and J.M. Launay Overexpression of the serotonin 5-HT2B receptor in heart leads to abnormal mitochondrial function and cardiac hypertrophy Circulation 107 25 2003 3223 3229 (Pubitemid 36793095)
87. A. Newman-Tancredi, D. Cussac, Y. Quentric, M. Touzard, L. Verriele, and N. Carpentier Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes J Pharmacol Exp Ther 303 2 2002 815 822 (Pubitemid 35231258)
88. P. Noize, M. Sauer, P. Bruneval, M. Moreau, A. Pathak, and H. Bagheri Valvular heart disease in a patient taking benfluorex Fundam Clin Pharmacol 20 6 2006 577 578 (Pubitemid 44762174)
89. G.M. Novaro, I.Y. Tiong, G.L. Pearce, M.S. Lauer, D.L. Sprecher, and B.P. Griffin Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis Circulation 104 18 2001 2205 2209 (Pubitemid 33043301)
90. K.D. O'Brien Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more) Arterioscler Thromb Vasc Biol 26 8 2006 1721 1728 (Pubitemid 44305324)
91. K.D. O'Brien, D.D. Reichenbach, S.M. Marcovina, J. Kuusisto, C.E. Alpers, and C.M. Otto Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis Arterioscler Thromb Vasc Biol 16 4 1996 523 532 (Pubitemid 26107723)
92. K.D. O'Brien, D.M. Shavelle, M.T. Caulfield, T.O. McDonald, K. Olin-Lewis, and C.M. Otto Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma Circulation 106 17 2002 2224 2230 (Pubitemid 35222217)
93. M. Olsson, C.J. Dalsgaard, A. Haegerstrand, M. Rosenqvist, L. Ryden, and J. Nilsson Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves J Am Coll Cardiol 23 5 1994 1162 1170 (Pubitemid 24117151)
94. M. Olsson, M. Rosenqvist, and J. Nilsson Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosis J Am Coll Cardiol 24 7 1994 1664 1671 (Pubitemid 24369191)
95. C.M. Otto Valvular Heart Disease 2004 Saunders Philadelphia
96. C.M. Otto, J. Kuusisto, D.D. Reichenbach, A.M. Gown, and K.D. O'Brien Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies Circulation 90 2 1994 844 853 (Pubitemid 24242754)
97. D. Parissis, A. Papachristodoulou, and A. Dimitriadis Inflammatory aneurysm of the abdominal aorta in a patient treated with ropinirole J Neurol 257 9 2010 1582 1584
98. A. Pazos, R. Cortes, and J.M. Palacios Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors Brain Res 346 2 1985 231 249 (Pubitemid 16241112)
99. D.V. Pechkovsky, A.K. Scaffidi, T.L. Hackett, J. Ballard, F. Shaheen, and P.J. Thompson Transforming growth factor beta1 induces alphavbeta3 integrin expression in human lung fibroblasts via a beta3 integrin-, c-Src-, and p38 MAPK-dependent pathway J Biol Chem 283 19 2008 12898 12908
100. S.L. Porvasnik, S. Germain, J. Embury, K.S. Gannon, V. Jacques, and J. Murray PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats J Pharmacol Exp Ther 334 2 2010 364 372
101. A.M. Pritchett, J.F. Morrison, W.D. Edwards, H.V. Schaff, H.M. Connolly, and R.E. Espinosa Valvular heart disease in patients taking pergolide Mayo Clin Proc 77 12 2002 1280 1286 (Pubitemid 35403801)
102. M. Pytliak, V. Vargova, V. Mechirova, and M. Felsoci Serotonin receptors - from molecular biology to clinical applications Physiol Res 2010
103. E. Rabkin-Aikawa, M. Farber, M. Aikawa, and F.J. Schoen Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves J Heart Valve Dis 13 5 2004 841 847
104. E. Rabkin, M. Aikawa, J.R. Stone, Y. Fukumoto, P. Libby, and F.J. Schoen Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves Circulation 104 21 2001 2525 2532 (Pubitemid 33104788)
105. E. Rabkin, S.P. Hoerstrup, M. Aikawa, J.E. Mayer Jr., and F. Schoen Evolution of cell phenotype and extracellular matrix in tissueengineered heart valves during in-vitro maturation and in-vivo remodeling J Heart Valve Dis 11 3 2002 308 314 discussion 314 (Pubitemid 34578445)
106. N.M. Rajamannan, W.D. Edwards, and T.C. Spelsberg Hypercholesterolemic aortic-valve disease N Engl J Med 349 7 2003 717 718
107. N.M. Rajamannan, M. Subramaniam, M. Springett, T.C. Sebo, M. Niekrasz, and J.P. McConnell Atorvastatin inhibits hypercholesterolemiainduced cellular proliferation and bone matrix production in the rabbit aortic valve Circulation 105 22 2002 2660 2665 (Pubitemid 34596044)
108. M.M. Rapport, A.A. Green, and I.H. Page Serum vasoconstrictor, serotonin; isolation and characterization J Biol Chem 176 3 1948 1243 1251
109. J.R. Raymond, Y.V. Mukhin, A. Gelasco, J. Turner, G. Collinsworth, and T.W. Gettys Multiplicity of mechanisms of serotonin receptor signal transduction Pharmacol Ther 92 2-3 2001 179 212 (Pubitemid 34251133)
110. M.M. Redfield, W.J. Nicholson, W.D. Edwards, and A.J. Tajik Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations Ann Intern Med 117 1 1992 50 52
111. S. Rosenkranz TGF-beta1 and angiotensin networking in cardiac remodeling Cardiovasc Res 63 3 2004 423 432 (Pubitemid 38970186)
112. A.B. Rossebo, T.R. Pedersen, K. Boman, P. Brudi, J.B. Chambers, and K. Egstrup Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis N Engl J Med 359 13 2008 1343 1356
113. B.L. Roth Drugs and valvular heart disease N Engl J Med 356 1 2007 6 9
114. B.L. Roth Irving Page Lecture: 5-HT(2A) serotonin receptor biology: Interacting proteins, kinases and paradoxical regulation Neuropharmacology 61 3 2011 348 354
115. B.L. Roth, R.D. Ciaranello, and H.Y. Meltzer Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors J Pharmacol Exp Ther 260 3 1992 1361 1365
116. B.L. Roth, S.C. Craigo, M.S. Choudhary, A. Uluer, F.J. Monsma Jr., and Y. Shen Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors J Pharmacol Exp Ther 268 3 1994 1403 1410 (Pubitemid 24100360)
117. B.L. Roth, T. Nakaki, D.M. Chuang, and E. Costa Aortic recognition sites for serotonin (5HT) are coupled to phospholipase C and modulate phosphatidylinositol turnover Neuropharmacology 23 10 1984 1223 1225 (Pubitemid 15201905)
118. B.L. Roth, D.L. Willins, K. Kristiansen, and W.K. Kroeze 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function Pharmacol Ther 79 3 1998 231 257 (Pubitemid 28393877)
119. B.L. Roth, and Z. Xia Molecular and cellular mechanisms for the polarized sorting of serotonin receptors: relevance for genesis and treatment of psychosis Crit Rev Neurobiol 16 4 2004 229 236
120. R.B. Rothman, M.H. Baumann, J.E. Savage, L. Rauser, A. McBride, and S.J. Hufeisen Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications Circulation 102 23 2000 2836 2841
121. R. Samarakoon, S.P. Higgins, C.E. Higgins, and P.J. Higgins TGFbeta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp 60(c-src)/EGFR(Y845) and Rho/ROCK signaling J Mol Cell Cardiol 44 3 2008 527 538
122. R. Schade, F. Andersohn, S. Suissa, W. Haverkamp, and E. Garbe Dopamine agonists and the risk of cardiac-valve regurgitation N Engl J Med 356 1 2007 29 38 (Pubitemid 46041751)
123. F.J. Schoen, and W.D. Edwards Valvular heart disease: general principles and stenosis M.D. Silver, A.I. Gotlieb, F.J. Schoen, Cardiovascular Pathology 2001 Churchill Livingstone New York, NY 402 442
124. V. Setola, M. Dukat, R.A. Glennon, and B.L. Roth Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor Mol Pharmacol 68 1 2005 20 33 (Pubitemid 41002941)
125. V. Setola, S.J. Hufeisen, K.J. Grande-Allen, I. Vesely, R.A. Glennon, and B. Blough 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro Mol Pharmacol 63 6 2003 1223 1229 (Pubitemid 36627216)
126. C.A. Simmons, G.R. Grant, E. Manduchi, and P.F. Davies Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves Circ Res 96 7 2005 792 799 (Pubitemid 40559519)
127. C. Skhirtladze, O. Distler, C. Dees, A. Akhmetshina, N. Busch, and P. Venalis Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis Arthritis Rheum 58 5 2008 1475 1484 (Pubitemid 351705937)
128. B.F. Stewart, D. Siscovick, B.K. Lind, J.M. Gardin, J.S. Gottdiener, and V.E. Smith Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study J Am Coll Cardiol 29 3 1997 630 634 (Pubitemid 27116107)
129. C. Tournois, V. Mutel, P. Manivet, J.M. Launay, and O. Kellermann Cross-talk between 5-hydroxytryptamine receptors in a serotonergic cell line. Involvement of arachidonic acid metabolism J Biol Chem 273 28 1998 17498 17503 (Pubitemid 28355082)
130. C. Ullmer, K. Schmuck, H.O. Kalkman, and H. Lubbert Expression of serotonin receptor mRNAs in blood vessels FEBS Lett 370 3 1995 215 221
131. J.R. Vane The relative activities of some tryptamine analogues on the isolated rat stomach strip preparation Br J Pharmacol Chemother 14 1 1959 87 98
132. G.A. Walker, K.S. Masters, D.N. Shah, K.S. Anseth, and L.A. Leinwand Valvular myofibroblast activation by transforming growth factorbeta: implications for pathological extracellular matrix remodeling in heart valve disease Circ Res 95 3 2004 253 260 (Pubitemid 39056285)
133. K.W. Walton, N. Williamson, and A.G. Johnson The pathogenesis of atherosclerosis of the mitral and aortic valves J Pathol 101 3 1970 205 220
134. A. Weill, M. Paita, P. Tuppin, J.P. Fagot, A. Neumann, and D. Simon Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus Pharmacoepidemiol Drug Saf 19 12 2010 1256 1262
135. D.M. Weiner, E.S. Burstein, N. Nash, G.E. Croston, E.A. Currier, and K.E. Vanover 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics J Pharmacol Exp Ther 299 1 2001 268 276 (Pubitemid 32905144)
136. M. Weintraub, J.D. Hasday, A.I. Mushlin, and D.H. Lockwood A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination Arch Intern Med 144 6 1984 1143 1148 (Pubitemid 14121061)
137. P.J. Wipff, D.B. Rifkin, J.J. Meister, and B. Hinz Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix J Cell Biol 179 6 2007 1311 1323 (Pubitemid 350277747)
138. J. Xu, B. Jian, R. Chu, Z. Lu, Q. Li, and J. Dunlop Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells Am J Pathol 161 6 2002 2209 2218 (Pubitemid 35434865)
139. S. Yabanoglu, M. Akkiki, M.H. Seguelas, J. Mialet-Perez, A. Parini, and N. Pizzinat Platelet derived serotonin drives the activation of rat cardiac fibroblasts by 5-HT2A receptors J Mol Cell Cardiol 46 4 2009 518 525
140. R. Young, N. Khorana, T. Bondareva, and R.A. Glennon Pizotyline effectively attenuates the stimulus effects of N-methyl-3,4- methylenedioxyamphetamine (MDMA) Pharmacol Biochem Behav 82 2 2005 404 410 (Pubitemid 41727953)
141. R. Zanettini, A. Antonini, G. Gatto, R. Gentile, S. Tesei, and G. Pezzoli Valvular heart disease and the use of dopamine agonists for Parkinson's disease N Engl J Med 356 1 2007 39 46 (Pubitemid 46041752)